Breast Cancer: Key Takeaways from Cantor's 2nd Annual Oncology Symposium

Research evidence excerpt

Breast Cancer: Key Takeaways from Cantor's 2nd Annual Oncology Symposium

Biopharmaceuticals | Biotechnology

EQUITY RESEARCH Industry Report

May 26, 2026

Breast Cancer: Key Takeaways from Cantor's 2nd

Companies mentioned

Ticker Price Rating Target Annual Oncology Symposium

ARVN $9.09 Overweight -

GILD $134.36 Overweight $155.00 We hosted Dr. Komal Jhaveri from MSKCC and Dr. Amy Tiersten from Mount

LLY $1,065.00 Overweight $1,230.00 Sinai at our Cantor Oncology Symposium for a discussion of clinical pearls

LONA $10.33 Overweight - on HR+/HER2- mBC (metastatic breast cancer), spanning 1L oral SERDs

MRK $122.41 Neutral $120.00 (selective estrogen degraders), lidERA in adjuvant (giredestrant, oral SERD;

PFE $25.90 Neutral $27.00 RHHBY, NC), PIK3CA and ESR1-specific regimens in 2L, and ADC sequencing.

RIGL $29.01 Neutral $38.00

Research Analysts: SERENA-4: The Bar Remains High for 1L Oral SERD Adoption

Carter Gould

212-915-1794 ●KOLs framed SERENA-4 (camizestrant + palbo (CDK4/6) vs anastrozole

Carter.Gould@cantor.com + palbo; AZN, NC) as an important catalyst for the ER+ field and the

Li Watsek SERD class, but emphasized that the efficacy bar remains high given

212-915-1221 the strength and tolerability of current 1L CDK4/6 + AI (aromatase Li.Watsek@cantor.com

inhibitor) regimens. Quantitatively, they pointed to a likely outcome of Ryan Chen

212-294-7862 an HR ~0.7–0.8, PFS ≥30 mos (+6 mos benefit vs. ~24 mos PALOMA,

Ryan.Chen@cantor.com which established AI + palbo in 1L), and eventual OS >60 mos as

Daniel Bronder, PhD clinically compelling benchmarks, with PALOMA's OS at ~53–54 mos.

212-610-2433

Daniel.Bronder@cantor.com

●The KOLs emphasized AI + CDK4/6 remain well tolerated, and any

regimen with additional monitoring or a more complicated safety